ELSEVIER

International Journal of Antimicrobial Agents 16 (2000) 565–571

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

www.ischemo.org

Volume contents

Volume 16 (2000)

No. 1

Leading Article

Genetic tools for the simultaneous identification of bacterial species and their antibiotic resistance genes: impact on clinical practice
M.G. Bergeron 1

Review

The fluoroquinolone antibacterials: past, present and future perspectives
P.C. Appelbaum and P.A. Hunter 5

Original Articles

Susceptibility of 1100 *Streptococcus pneumoniae* strains isolated in 1997 from seven Latin American and Caribbean countries
M.R. Jacobs, P.C. Appelbaum and LASER Study Group 17

Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against *Mycobacterium tuberculosis* and *Mycobacterium avium* complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines
K. Sato, H. Tomioka, T. Akaki and S. Kawahara 25

Spectrum and transferability of β-lactam resistance in hospital strains of *Enterobacter* isolated in Bratislava and Innsbruck
H. Bujdáková, J. Klimáčková, F. Allerberger, M. Moravčíková, M. Bagová, J. Hanzen, D. Michálková-Papajová, M.P. Dierich and M. Kettner 31

Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS
J.C. McNabb, R.C. Owens, D. Xuan, R. Quintiliani, C.H. Nightingale and D.P. Nicolau 37

The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers
A. Allen, E. Bygate, D. Clark, A. Lewis and V. Pay 45

Commentary

The millennium bugs — the need for and development of new antibacterials
R. Bax, N. Mullan and J. Verhoef 51

Short Communications

In vitro activity of GAR-936 against *Chlamydia pneumoniae* and *Chlamydia trachomatis*
P.M. Roblin and M.R. Hammerschlag 61

Antibiotic resistance among enterococcal strains isolated from clinical specimens
Z. Barišić and V. Punda-Polić 65

Comparative in vitro activity of phenothiazines against multidrug-resistant *Mycobacterium tuberculosis*
M.V. Bettencourt, S. Bosne-David and L. Amaral 69

Propyl gallate increases in vitro antifungal imidazole activity against *Candida albicans*
V. Strippoli, F.D. D'Auria, M. Tecca, A. Callari and G. Simonetti 73

Letters

Antimicrobial resistance of clinical isolates of *Streptococcus pneumoniae* in Istanbul
N. Gönüllü and R. Berkiten 77

The relationship between resistance in bacteria and antibiotic use in neurology and haematology units
Y. Krupova and J.C. Gould 79

Instructions to authors 81

No. 2

Editorial

J. Klastersky 83

Introduction

Febrile neutropenia: a necessary evil?
M.H.N. Tattersall 85

Original Articles

Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients
J. Bille 87

Radiological and invasive diagnosis in the detection of pneumonia in febrile neutropenia
V. Ninane 91

Unusual presentations of infection in neutropenic patients
G.P. Bodey 93

New pathogens in neutropenic patients with cancer: an update for the new millennium
S.H. Zinner 97

Therapeutic guidelines for *Pseudomonas aeruginosa* infections
H. Giamarellou 103

Risk factors assessment in febrile neutropenia
M. Paesmans 107

Prediction of neutropenia
K.V.I. Rolston 113

Colony stimulating factors in patients with fever and neutropenia
E.B. Rubenstein 117

Antibacterial prophylaxis
M. Cruciani 123

Febrile neutropenia: antifungal prophylaxis
J.P. Donnelly 127

Empirical treatment of sepsis in neutropenic patients
J. Klastersky 131

Management of fungal infections in neutropenic patients: more doubts than certainties?
A. Del Favero 135

Modifications of therapy
W.V. Kern 139

Standard antifungal therapy in neutropenic patients
M. Aoun 143

New antifungal agents and preparations
B.E. De Pauw 147

Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
T.J. Walsh, M. Roden, E. Roilides and A. Groll 151

Antiviral therapy of herpes simplex
R. Snoeck 157

Prevention and management of mucositis in patients with cancer
J. Herrstedt 161

Intravenous access: related problems in oncology
M. Viot 165

Out-patient management of febrile neutropenia
J.A. Talcott 169

Febrile neutropenia in children
F. Crokaert 173

Febrile neutropenia in allogeneic transplantation
R. De Bock and A.Z. Middelheim 177

Medical economic considerations of supportive cancer care
T.D. Szucs 181

Multinational cooperation in trials and guidelines dealing with febrile neutropenia
R. Feld 185

Instructions to authors 189

No. 3

Review
Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem
D. van der Waaij and C.E. Nord 191

Commentary
Licensing new antibacterial agents — a European perspective
M. Powell 199

Original Articles
Activity of voriconazole against *Candida albicans* and *Candida krusei* isolated since 1984
J.K. Lee, D. Peters, A.A. Obias, G.A. Noskin and L.R. Peterson 205

Natural antibiotic susceptibility of *Salmonella enterica* strains
I. Stock and B. Wiedemann 211

Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B *Streptococcus pneumoniae* in Greece, Italy and Israel
G.A. Syrogiannopoulos, F. Ronchetti, R. Dagan, I. Grivea, M.P. Ronchetti, N. Porat, T.A. Davies, R. Ronchetti, P.C. Appelbaum and M.R. Jacobs 219

In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria
R. Schaumann, G. Ackermann, B. Pless, M.C. Claros, E.J.C. Goldstein and A.C. Rodloff 225

Outer membrane changes in *Pseudomonas stutzeri* resistant to chlorhexidine diacetate and cetylpyridinium chloride
U. Tattawasart, J.-Y. Maillard, J.R. Furr and A.D. Russell 233

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections
K.G. Naber, K. Hollauer, D. Kirchbauer and W. Witte 239

Short communications
Factors affecting the variation in antibiotic resistance of *Helicobacter pylori* over a 3-year period
M. Ferrero, J.A. Ducóns, B. Sicilia, S. Santolaria, E. Sierra and F. Gomollón 245

Decrease of antibiotic resistance in *Salmonella typhi* isolated from patients attending hospitals of Dhaka City over a 3 year period
S.M. Zahurul Haque Asna and J. Ashraful Haq 249

Correspondence
A 10 year study of resistance of Staphylococcus aureus 10 selected antimicrobials in three Venezuelan Centre
A.J. Rodriquez, C.N. Rodriquez, P. Meijomil, A. Garcia, C. Duque, M. Molina 253

First report of ampicillin and glycopeptide resistant Enterococcus faecium VanA bacteraemia in Greece
G. Kouppari, H. Papadaki, C. Arida, J. Sakellariou, N.J. Legakis, J. Papaparaskevas 254

Special Section
International Meeting on Antimicrobial Chemotherapy in Clinical Practice ACCP

Respiratory Tract Infection
Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy
G. Cornaglia and R. Fontana 259

New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
P. Ball 263

Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone
B. Meinl, J.M. Hyatt, A. Forrest, S. Chodosh and J.J. Schentag 273

The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia
J.A. García-Rodríguez and J.L. Muñoz Bellido 281

What's new in streptococcal pharyngitis
A. Boccazzi, P. Tonelli and R. Ceruti 287

Antibiotic Usage
The role of the hospital pharmacist in cost control and antibiotic policy
G. Milkovich 291

Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy
M. Bassetti, A. Di Biagio, B. Rebesco, G. Cenderello, M.E. Amalfitano and D. Bassetti 295

Sequential or switch treatment — which criteria should be fulfilled?
P.M. Shah 301

The role of antimicrobial policies in neutropenic patients
P. Martino and C. Girmenia 303

Antibiotic usage and resistance — trends in Estonian University Hospitals
P. Naaber, S. Kõljalg and M. Maimets 309

Antifungal Drugs
Current and future antifungal therapy: new targets for antifungal therapy
V.T. Andriole 317

Making the diagnosis of fungal infection: when to start treatment
P. Martino and C. Girmenia 323

Mechanisms and clinical significance of antifungal resistance
J. Bille 331

Miscellaneous topics
Emerging and reemerging pathogens
R. Gomez-Lus, A. Clavel, J. Castillo, C. Seral and C. Rubio 335

Anaerobic infection therapy
H. Giamarellou 341

Ciprofloxacin versus chloramphenicol in the treatment of salmonella infection
A. Liberti and L. Loiacono 347

Virological infections
Does HGV–HIV co-infection exist?
E. Pontali, P. Pedemonte, M. Bassetti, S. Boni and D. Bassetti 349

Cellular factors involved in the induction of resistance of HIV to antiretroviral agents
O. Turriziani, G. Antonelli and F. Dianzani 353

Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects
K. de Gaetano Donati, S. Bertagnolio, M. Tumbarello, E. Tacconelli, M. Cataldo, B. Longo and R. Cauda 357

Tolerance of highly active antiretroviral therapy in HIV patients: a 3-year follow up
A. Beltrame, V. Del Bono, M. Marturano, P. Pedemonte, R. Rosso, G. Mazzarello, M. Bassetti, A. Collidà, F. Fusco and D. Bassetti 361

Analysis of drug costs in a domiciliary care unit for AIDS patients: a 3-year survey
A. Beltrame, D. Gori, F. Marenco, D. Bassetti and F. Henriquet 363

Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors
P. Fiore, E. Donelli, S. Boni, E. Pontali, R. Tramalloni and D. Bassetti 365

Compliance to combination antiretroviral therapy in HIV-1 infected children
S. Boni, E. Pontali, P. De Gol, P. Pedemonte and D. Bassetti 371

Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients
T. Prestileo, G. Mazzola, F. Di Lorenzo, P. Colletti, F. Vitale, D. Ferraro, R. Di Stefano, C. Cammà and A. Craxì 373

Instructions to authors 379

No. 4

Review
Methylene blue derivatives — suitable photoantimicrobials for blood product disinfection?
M. Wainwright 381

Original Articles
β-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing β-lactamases of gram-negative extraintestinal clinical isolates
Z. Gál, D. Szabó, P. Kovács, F. Hernádi, B. Tóth-Martinez and F. Rozgonyi 395

Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997–1998
E. Huczko, B. Conetta, D. Bonner, L. Valera, T. Stickle, A. Macko and J. Fung-Tomc 401

Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses
A.A. Firsov, S.H. Zinner, I.Y. Lubenko and S.N. Vostrov 407

Letter
Studies on the genotoxicity of turmeric extracts in bacterial system
A. Pal and A.K. Pal 415

Special Section
International meeting on Resistance to Antimicrobial Agents (RAA)

New concepts for future control of HIV derived from studies of pathogenesis
R.C. Gallo 421

Clinical impact of antiretroviral resistance testing: current problems and future directions
S. Rusconi and M. Moroni 425

Resistance to antiretroviral drugs in patients with primary HIV-1 infection
B. Brenner, M.A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R.-P. Sekaly, B. Conway, J.-P. Routy and Investigators of the Quebec Primary Infection Study 429

Genotyping in HIV drug resistance mutations: epidemiology in 145 patients
M. Rosina, V. Micheli, S. Besana, C. Toia, M.R. Gismondo and A. Cargnel 435

Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure
J. Schüpbach, Z. Tomasik, D. Nadal, B. Ledergerber, M. Flepp, M. Opravil and J. Böni 441

Laboratory diagnosis of human cytomegalovirus (HCMV) central nervous system disease in AIDS patients
C.C. Ginocchio 447

Use of CMV transcripts for monitoring of CMV infections in transplant recipients
G. Gerna, F. Baldanti, J. Middeldorp and D. Lilleri 455

Cytomegalovirus pp65 antigenemia in HIV patients: retrospective on 3 years study
A. Lombardi, L. Drago, M.R. Bartolone and M.R. Gismondo 461

Epidemiology of HIV-1 and emerging problems
V.V. Lukashov, A. de Ronde, J.J. de Jong and J. Goudsmit 463

Bacterial agents of lower respiratory tract infections (LRTIs), β-lactamase production, and resistance to antibiotics in elderly people
C.M. Sanguinetti, F. De Benedetto, G. Miragliotta and DEDALO Study Group 467

Antibiotic resistance in Gram-positive cocci
J. Jeljaszewicz, G. Mlynarczyk and A. Mlynarczyk 473

Epidemiology of Gram-negative antibiotic resistance in outpatients: a year of surveillance
L. Drago, B. Mombelli, E. De Vecchi, L. Tocalli, G. Nardi and M.R. Gismondo 479

Resistance of bacteria in urinary tract infections
M. Chomarat 483

The impact of resistance on the management of urinary tract infections
A.M. Sefton 489

Changes in the resistance patterns among upper respiratory tract infection pathogens
S. Stefani 493

Short-course treatment for acute tonsillopharyngitis
S. Esposito and T. Ascione 495

New technologies and applications of PCR in clinical diagnosis
G. Colucci 499

Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics
A. Novelli, S. Fallani, M.I. Cassetta and S. Conti 501

Strategies to treat patients with antibiotic resistant *Helicobacter pylori*
F. Mégraud 507

The intensive care physician and control of antimicrobial resistance
B.M. Graf and E. Martin 511

Iron deficiency anaemia and *Helicobacter pylori* infection
B. Annibale, G. Capurso, G. Martino, C. Grossi and G. Delle Fave 515

Treatment and prevention of antibiotic associated diarrhea
E. Bergogne-Bérézin 521

Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic
G. Corti, R. Cinelli and F. Paradisi 527

The use of probiotics in medical practice
B. Mombelli and M.R. Gismondo. 531

Is there in vivo–in vitro correlation between antifungal susceptibility, species of *Candida* spp. and clinical outcome?
V. Krcmery Jr 537

Antifungal therapy in thoracic cancer patients with low dose liposomal amphotericin B (AmBisome)
C. Lequaglie, G. Giudice, P.P.B. Massone and I. Cataldo. 541

Candida albicans cellular internalization: a new pathogenic factor?
L. Drago, B. Mombelli, E. De Vecchi, C. Bonaccorso, M.C. Fassina and M.R. Gismondo 545

Pneumocystis carinii diagnosis: an update
F. Agostoni, C. Atzori, E. Angeli, A. Mainini, V. Micheli and A. Cargnel 549

Author index 559
Volume contents 565
Instructions to authors 573